Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Milton S. Hershey Medical Center
Mayo Clinic
Thomas Jefferson University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Istari Oncology, Inc.
Memorial Sloan Kettering Cancer Center
University of Alabama at Birmingham
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Wake Forest University Health Sciences
Case Comprehensive Cancer Center
Case Comprehensive Cancer Center
Lumos Pharma
Emory University
University of California, San Francisco
University of Washington
Medical College of Wisconsin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
City of Hope Medical Center
City of Hope Medical Center
City of Hope Medical Center
Radiation Therapy Oncology Group
Wake Forest University Health Sciences
Memorial Sloan Kettering Cancer Center
University Hospital, Montpellier
Duke University
National Cancer Institute (NCI)
City of Hope Medical Center
National Cancer Institute (NCI)
Indiana University
National Cancer Institute (NCI)
Duke University
Duke University
University of California, San Francisco
INSYS Therapeutics Inc
University of Pittsburgh
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Centre Hospitalier Universitaire Vaudois
Novartis
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)
Duke University
Duke University